Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

May 11, 2023

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 61 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and thanks for holding. I'd like to welcome you to the conference call for investors and analysts that Bayer is holding on its results for the first quarter of 2023. During the recorded presentation today, everyone attending will be able to listen only. After the presentation, there will be a session for questions and answers. Should anyone on the line have trouble hearing the conference, you can press the star key and then 0 on your phone to reach an operator for help. At this point, I'll hand the conference over to Oliver Maier, who leads Investor Relations at Bayer AG. Oliver, please go ahead.

Oliver Maier

executive
#2

Thanks so much, Natalie. Good afternoon, and thank you all for being with us today. I want to welcome everyone to our conference call for the first quarter of 2023. Joining me on the call today is Werner Baumann, our CEO. I need to offer an apology for Wolfgang Nickl, our CFO, since he became really ill yesterday and is unable to be with us today. We're making Werner work really hard today, because he has to read the entire part. The businesses are represented by the responsible board members for the Q&A session. Werner will kick off today's call by framing the first quarter, and after that he will comment on the drivers behind our business performance, along with the outlook for 2023, before we open the Q&A session. As always, I'd like to begin today's call by drawing your attention to the cautionary language contained in our safe harbor statement, as well as in all the materials that have been distributed today. With that, I'll hand it over to you, Werner.

Werner Baumann

executive
#3

Okay. Thanks, Oliver. Good afternoon, everyone. I'm glad to have you join us for our first-quarter conference call. Compared with a very strong prior year, the first quarter was soft. Broadly speaking, we had expected this, given the volatile glyphosate dynamics and the current realization profile, with performance improving toward the second half of 2023. If we set the glyphosate dynamics aside for a moment, the rest of our Crop Science portfolio did very well. With 8% currency- and portfolio-adjusted growth, we are fully on track. We posted double-digit % sales increases, especially in corn seeds and traits and in insecticides. In pharmaceuticals, our launch assets kept up their strong momentum. Nubeqa again more than doubled sales in quarter one and gained market share. Kerendia entered our top 15 products for the first time. We also see solid contributions from Eylea again. In our consumer health division, we saw strong growth in the allergy, cough and cold, and dermatology categories, partially offset by a consolidation in the nutritional segment. As we already shared on our last conference call, the first quarter was impacted by foreseen transitional happens for our pharma business in China. This was A, driven by the COVID-19 wave, holding back sales across the portfolio.

Werner Baumann

executive
#4

Regarding B, the effect of volume-based procurement—especially for Avodart—we expect patient flow in China to bounce back over the course of the year. We also still anticipate a broad improvement in performance during the second half of 2023, since we look for growing contributions from our launch assets to help us. The single key variable in our year-on-year results concerns the anticipated decrease in glyphosate-based service sites. Generic reference pricing has fallen more quickly than we expected in quarter one. Solid results across the rest of the non-glyphosate portfolio allowed us to offset this almost entirely for the quarter. Our assumption is that the faster normalization in glyphosate will persist through the rest of the year. Taken together, this produces a more subdued outlook at the divisional level for Crop Science. Even with the steeper drop in glyphosate-based service sites and ongoing inflationary pressure, we intend to safeguard our bottom line through continued active pricing management across the remaining portfolio as well as further cost savings measures. At group level, our revised plan is still consistent with the lower end of our guidance range. Let's turn now to our customary update on innovation progress since the previous call. In our late-stage Pharma pipeline, we have started a phase III trial, ARASTEP, to examine how efficacious Nubeqa is in patients who have biochemical recurrence.

Werner Baumann

executive
#5

Assuming the study finishes successfully, this might allow Nubeqa to reach prostate cancer patients at earlier disease stages as well. In the meantime, we keep expanding Nubeqa's use in the metastatic hormone-sensitive prostate cancer setting through label expansions across various regions such as Japan, the E.U., and China. For Eylea 8 mg, we are pursuing approval in Japan for treating two major retinal diseases: neovascular wet age-related macular degeneration and diabetic macular edema. To potentially extend Eylea 8 mg to patients with macular edema secondary to retinal vein occlusion, we announced the start of the phase III study QUASAR just yesterday. Lastly, we are also very glad to report that patient recruitment in our Asundexian phase III OCEANIC program remains strong, surpassing all of our original expectations. In crop science, we have successfully begun field trials for our Preceon smart corn system in the U.S., covering more than 30,000 acres with roughly 300 farmers taking part. We eagerly await their feedback on this transformational corn production system, which combines three elements: our short stature corn hybrids, digital insights, and tailored support.

Werner Baumann

executive
#6

Additionally, in corn, we expect SmartStax PRO, featuring RNAi technology that controls corn rootworm, to exceed 1 million acres during this season. On the cotton side, ThryvOn has now been introduced in the U.S. — the first trait we have ever brought forward for managing piercing sucking pests. Each of these technologies moved us forward on our twin objectives: generating more output while consuming fewer resources, and helping growers sustain food systems. To wrap up this section, I want to flag two innovation events we have planned — the Crop Science Innovation Summit on June 20th and the Pharma R&D Event on June 28th — both of which I strongly encourage you to attend. Now let me turn to quarter one and what drove our business, and then I'll cover the financial outlook for the full year. Group sales reached EUR 14.4 billion, essentially matching the stronger prior-year figure. We observed quicker normalization of glyphosate market conditions, together with the anticipated headwinds affecting our pharmaceutical products in China, which were nearly offset by a very solid showing across the remaining businesses. EBITDA before special items fell 15% to EUR 4.5 billion, driven mainly by smaller contributions from glyphosate-based herbicides relative to Q1 2022, persistently elevated cost inflation, and continuing investment in pharma innovation.

Werner Baumann

executive
#7

After that, EBITDA margin before special items was 31.1%. Core earnings per share reached EUR 2.95, a touch above what the market had expected for the quarter and, as anticipated, under an exceptionally strong prior-year figure of EUR 3.53, largely because of the business effects already described. Our core financial results rose year on year, helped by greater interest income from money market funds and by favorable fair value movements in planned asset and debt investments stemming from improved capital market performance. The core tax rate was 23.6%, consistent with our guidance for the full year. Free cash flow stood at minus EUR 4.1 billion in quarter one 2023, versus minus EUR 1.2 billion a year earlier. That decrease reflects larger litigation payouts tied to the PCB settlements we announced previously, along with weaker contributions from the divisions. As you know, our cash profile by quarter, especially in Crop Science, follows a strongly seasonal pattern, and the biggest inflows are anticipated in the second half of the year. Net financial debt climbed to EUR 36.1 billion by the close of the first quarter. This too reflects the settlement payouts and the seasonal pattern in our cash flows that I just described. In our Crop Science division, sales fell 1% on a currency- and portfolio-adjusted basis against an outstanding prior-year quarter.

Werner Baumann

executive
#8

The bridge shows sales of glyphosate-based herbicides falling 50%, roughly EUR 700 million, in the first quarter. Even so, we nearly offset that drop because the rest of the business grew sales by more than 8%. Within that, pricing contributed a benefit of more than 11%, which offset a 3% volume decline. Corn seeds and trades got off to a very good start to the year, with sales up 16% on a currency- and portfolio-adjusted basis. That growth came chiefly from price increases in North America and EMEA. In the U.S., higher volumes from anticipated higher planted acres and share gains were offset by lower volumes in EMEA, where we expect lower acreage in Ukraine because of the ongoing war. Our insecticide portfolio also grew by double digits, driven mainly by significant price and volume increases from how our Movento product performed against sucking pests in EMEA. Soybean seeds and trades posted a slight sales increase, predominantly from higher volumes in Brazil. In North America, though, lower volumes—partly tied to phasing into the prior quarter—could not be entirely offset by higher pricing. On the bottom line, EBITDA before special items fell 11% to EUR 3.3 billion, mainly impacted by the decline in glyphosate-based herbicides.

Werner Baumann

executive
#9

On top of that, cost inflation is still running hot, adding up to roughly EUR 300 million during the first quarter. We managed to offset part of those negative effects through robust pricing across the rest of our portfolio, contributions from efficiency programs already in place, and a favorable currency impact. EBITDA margin before special items reached 39.1%, which leads the industry and is a touch above the 36%-38% range we had projected for the quarter. Net sales landed between EUR 4.1 billion and EUR 4.4 billion, a decline of 3% versus the prior-year quarter on a currency- and portfolio-adjusted basis. Results for the quarter took a significant hit from a temporary soft patch in China. Much like other pharma companies with a strong China position were seeing, January sales there were nearly cut in half. Specifically, the COVID-19 outbreak early in the year produced a mid-double-digit sales drop in that region, hitting almost every part of the portfolio, and Xarelto most of all. Beyond that, we faced the anticipated volume-based procurement pressure on Adalat. Among our launch assets, we saw strong growth in new prescriptions for Nubeqa and Kerendia in the United States. Nubeqa again more than doubled its sales relative to quarter 1 2022 and kept picking up market share.

Werner Baumann

executive
#10

For Nubeqa in the U.S., it now ranks second among second generation ARIs in the non-metastatic and metastatic patient groups, and it's on the verge of taking the number 2 spot in metastatic patients too. First-quarter Kerendia sales more than tripled, reflecting ongoing U.S. market uptake along with rising contributions from markets outside the U.S. As for our strategic focus countries, we keep expanding our U.S. footprint. Divisional sales in the United States rose 6%, so we clearly beat other geographies. Turning to market leading Eylea, volume growth continued across every region, which more than offset price declines in Europe. Beyond that, our market leading radiology business kept contributing through higher volumes and price increases. EBITDA before special items reached EUR 1.1 billion, a corresponding margin of 25.1%. That reflected the lower top line, the product mix effect and inflation headwinds. We also stepped up R&D investments into platform companies and our late-stage pipeline, which is likewise a consequence of the positive and strong patient recruitment dynamics for the Asundexian trial. Shifting to consumer health, we delivered solid growth once again. Net sales rose 4% on a currency and portfolio adjusted basis to EUR 1.6 billion, on top of a high prior year comparable.

Werner Baumann

executive
#11

With price elasticity rising, supply temporarily constrained, and inflationary pressure proving sticky, our targeted, active approach to pricing offset the volume drops we recorded during the first quarter. In our allergy category, innovation generated substantial growth of 16%, helped meaningfully by Astepro. The rest of our allergy portfolio likewise delivered robust growth. We kept marketing our Bepanthen Derma line successfully, and that underpinned growth in dermatology. Because cold and flu incidence stayed elevated, cough and cold sales rose sharply by 16%, building on an exceptionally strong prior year. Following 3 years of considerable expansion, nutritionals fell by 10%. We have confidence that this category will come back to healthy growth across the full year. EBITDA before special items landed where anticipated, at EUR 379 million, a margin of 24.1%. Our operational efficiency programs and active pricing management contributed enough to offset margin pressure caused by high cost inflation and constrained supply. Simultaneously, we sustained our sizable investments in innovation. Turning to our guidance for the full year: at the divisional level, the principal change sits in Crop Science, reflecting a quicker than anticipated fall in glyphosate market prices.

Werner Baumann

executive
#12

Our current projection is that sales of glyphosate-based herbicides will fall by about EUR 1.7 billion at the midpoint, versus the EUR 900 million we indicated earlier. At the same time, in the rest of the Crop Science business, we expect currency and portfolio adjusted growth to speed up to roughly 10%, compared with the 8% we mentioned previously. In our outlook we still assume double-digit percentage sales growth for corn, fungicides, and insecticides, backed by the innovation we are bringing to market and by strong pricing. How the outlook develops quarter by quarter is also heavily shaped by trends in glyphosate-based herbicide sales, and most of the expected downturn will land in the first half of the year. Consequently, we now anticipate that divisional sales will decline in the second quarter, then recover slightly in quarter three and finish the year strongly, mainly in Latin America. All told, we now expect currency and portfolio adjusted growth of about 1.5% for the division in 2023. To offset incremental inflation and the glyphosate downside, we have put additional cost savings measures in place. For Crop Science, we now expect savings and efficiency measures to contribute a total of more than 500 million. The EBITDA margin before special items is expected to land at the lower end of our previous range, which is approximately 25% now.

Werner Baumann

executive
#13

Our outlook for pharmaceuticals and consumer health is unchanged. We’re reiterating the phasing assumptions we shared before. In pharmaceuticals, that means a first half clearly below the second half, on both top and bottom line, since we’ll see offsetting dynamics from our launch assets later in the year. For the group, we confirm full year guidance updated toward the lower end of the ranges provided for net sales, EBITDA before special items and core earnings per share. Our net debt financial debt guidance is anticipated to come in at the higher end of the range we gave you. On FX, we updated our estimate for March closing rates. We would now expect a stronger top-line headwind of about EUR 1.7 billion. To be very clear, for all other KPIs, we do not project a material FX impact based on the rates we currently have for the remainder of 2023 and beyond. Before I close, please also note that we recently entered a renewable energy certificate agreement that secures long-term access to sustainable energy for our Crop Science Soda Springs site in the U.S.

Werner Baumann

executive
#14

There's an embedded derivative in this contract, and starting in quarter two we'll begin measuring it at fair value. So with that said, I'll turn things back over to Oliver so we can kick off our Q&A.

Oliver Maier

executive
#15

Thanks. Werner, I really appreciate that overview. Before we get started, a quick reminder: please limit yourselves to roughly 2 questions each, which lets us get to as many participants as possible within the time we have. And to keep the audio quality good, as usual, we ask that you use a speaker or a landline rather than a headset or a cell phone. With that, Natalie, I believe we're ready to open the lines for questions.

Operator

operator
#16

Thank you. Ladies and gentlemen, we're going to start the question-and-answer portion at this point. Should you have a question, kindly press star and then one on your phone. To withdraw your question, press star and then two. Should you be on speaker equipment today, please pick up the handset prior to making your selections. Please hold a moment for the first question. Our first question comes from Michael Leuchten at UBS. Please go ahead.

Michael Leuchten

analyst
#17

Thank you. I have two questions, please. The first is about pharma. You were quite clear that January especially was very weak, but I assume you were aware of that when you established the guidance back in February. Now, the 25% margin in the first quarter is a rather steep curve to reach your target for the full year, particularly given the phasing you reiterated, with H1 significantly below H2. I was wondering whether you could give us some color on the dynamics that let you get to your above 29% from the 25% margin in Q1. A question for Rodrigo. Volume in Q1 was down quite meaningfully, yet you're making it very clear that underlying performance is good and that you're very confident in an even better performance of 10% underlying for the full year, up from 8% previously. Can you talk to phasing? Can you talk to, sort of, buying behavior? What have you seen in March relative to February, perhaps in buying behavior, particularly on the crop protection side, that gives us a bit of color on why you think we're going to see that improved momentum also on the volume side coming out of that soft spot in Q1?

Michael Leuchten

analyst
#18

I appreciate that.

Oliver Maier

executive
#19

Thanks, Michael. Stefan, you go first. There you are.

Stefan Oelrich

executive
#20

Hi. Hello, Michael. This is Stefan speaking. I appreciate the question. Naturally, what we're looking for is steady gains — sequential gains through the quarter on the top line — which clearly leads to better margins as well. Keep in mind that, since we've discussed China at such length, the first quarter was somewhat of a perfect storm in that market, with essentially no meaningful business at all in January, on top of VBP Adalat taking effect. Several of those effects ease as the year goes on. In fact, we ought to be back in growth territory in China during the fourth quarter. Turning to the rest of the business, we have encountered some — and will keep encountering some — headwinds on Xarelto right across the board. I suppose that's the new normal for us. We're offsetting that very effectively with our launches. We anticipate steady gains from one quarter to the next, though we also have to maintain rigorous cost discipline, since this is clearly not an easy situation to climb out of.

Oliver Maier

executive
#21

Rodrigo?

Rodrigo Santos

executive
#22

Yes. Thanks for the question. As you point out, we're guiding for 10% growth in our core business, and we saw 8% growth in the first quarter, mainly driven by price and by your question on volume. There are three or four elements I want to highlight regarding volume and why we're confident we're going to see that. Let me start with the important one, our fungicide business. When you think about the last quarter of last year and the beginning of this year, we had some supply constraints. The good news is that we're going to be back on track on supply for the remainder of the year. This is good because mainly the market for us is in Latam, where we have Q3 and Q4 that we're expecting to supply a good volume of fungicide on a growing market. That's a first element. The second element of volume specifically is that this year you see a little bit of a shift from Q1 to a later stage of the year of the farmers' behavior, and we saw a little bit of that in the market. We're going to see more of the volume. A good example of that, glyphosate, we're going to see higher volumes at the end of the year as well because of that behavior.

Rodrigo Santos

executive
#23

And then there's a volume factor that's specific to the first quarter, which is the situation in Ukraine, right? Sadly, on account of the war, you're going to see a reduction in corn area in Ukraine, and that had an impact as well. Again, looking at the core business, we saw very significant growth in corn seeds and traits, and in insecticides. Fungicides are what I said would mainly come in Q3 and Q4, with a particular impact in Latam. Also, we're going to see somewhat higher volume on glyphosate toward the end of the year. Thank you for your question.

Oliver Maier

executive
#24

Thanks, Rodrigo.

Operator

operator
#25

Our following question comes from Richard Vosser at JPMorgan. Go right ahead.

Richard Vosser

analyst
#26

Hello, and thank you for allowing me to ask. On my first question, I'd like to return to glyphosate pricing. In what way should we consider the gains you made from glyphosate pricing during 2021 possibly unwinding across the coming 12 to 18 months? As you are aware, current generic glyphosate pricing sits at roughly the level seen in the first half of 2021. I understand you now stand at EUR 2 billion. That reflects the reversal of 2022, so how should we view those 2021 benefits over the next 12 to 18 months? For my second question, I was hoping you might give us a bit more detail on the FX dynamics and explain why the top line faces a growing headwind while EBITDA and core EPS see no meaningful headwind. Related to that, if you can, it would be really helpful to hear your reported margin guidance by division. I believe the margin guidance is CER; some indication of the reported margin guidance would be useful. Many thanks.

Werner Baumann

executive
#27

Okay, Rodrigo, would you like to kick things off with glyphosate?

Rodrigo Santos

executive
#28

Okay, so let me take up the glyphosate question. Given the guidance revision we just made, we're essentially acknowledging that price as early as 2021, as you put it — rather than in the second half of 2021, where we're beginning to observe somewhat higher pricing. We've essentially adjusted for all the favorable pricing effect we saw in 2022. That has now been reflected in this guidance. Basically, through the EUR 1.7 million adjustment we just announced, there's a mix of pricing alongside higher volume. Just to give you some sense of it — with the adjustment we made, we believe we're capturing something closer to glyphosate's historical pricing, and we feel that's the right place to be at this point. Thank you.

Werner Baumann

executive
#29

Okay, Richard. I’ll go over FX quickly. I’ll restate my earlier point: on the top line, yes, there is that negative EUR 1.7 billion. And on the bottom line, relative to what we provided to you, it is neutral. That is somewhat counterintuitive, and the explanation is that when we provide prior-year FX, we always also include the prior-year hedging, which we experience on an as-if basis. That was -EUR 500 million last year. It is being backed out and then offset by the negative FX that we actually have on the bottom line this year, which means the figures you have with the range, with the lower range, are what you would see for 2023 and also going forward. There is no additional erosion from FX effects at current rates entering the figures, neither for 23 nor beyond, to be very clear about that. Regarding margin guidance, you know, just, let’s say, as a back-of-the-envelope matter, you should assume no material change to the margin guidance for the full year. You know, there may be, let’s say, a few tenths of % margins up and down, you know, across the divisions, but there is no material change to the margin guidance provided.

Richard Vosser

analyst
#30

Much appreciated. That's really useful.

Werner Baumann

executive
#31

Thanks, Richard.

Operator

operator
#32

We’ll take the next question from James Quigley at Morgan Stanley. Go right ahead.

James Quigley

analyst
#33

Thanks for taking my questions. I have two, please. First, on the Crop Science business and those incremental cost savings: could you give us a sense of where they'll come from, ideally broken out by line item? How much more savings might still be available? How lean is the organization at this point, and where could it get to, given that these savings almost appear out of nowhere to rescue the margin? My second question is a product question in pharma. This marks the second quarter in a row that we've seen the Kogenate or Kovaltry hemophilia portfolio decline. Altuviiio from Sanofi is launching. What's your view on the potential risks to the hemophilia franchise? Have you seen any impact? I think it's very early days, but have you seen any impact from that launch on the portfolio so far? Thank you.

Rodrigo Santos

executive
#34

Let me begin with the savings you brought up in Crop Science. We're still carrying out what we refer to as Transform to Win, correct? Among the steps we took last year — and we disclosed some savings then, with additional ones coming this year — is driving efficiency across the whole organization and making trade-offs with certain resources we had. That carried on strongly into this year. On top of that, we're layering in some contingent savings so we can offset part of the downsides we encountered with glyphosate. That covers travel costs, flexible spending, and how we streamline certain work by leaning heavily on the tools we already use today, such as virtual meetings and so forth. The overall savings we were projecting come to EUR 500 million, and that figure is made up of all these pieces. Transform to Win initiatives, efficiency gains across the organization, some genuine OpEx savings from the travel reductions we have, and other tools we have in the plan. Taken together, these are all actions we're putting in place to support us through the year, consistent with how we're guiding for the year as well.

Rodrigo Santos

executive
#35

Stefan?

Werner Baumann

executive
#36

Yeah. Hi, James. It was really difficult to make out what you were saying. From what I could catch, your question was about how our hemophilia business is progressing sequentially. I hope I've got that right. Could you confirm that quickly?

James Quigley

analyst
#37

That comes from building out the hemophilia franchise step by step, plus the possible competitive effect of BIVV001 — Altuviiio from Sanofi.

Werner Baumann

executive
#38

So what do we expect going forward? To start with, our first quarter is being measured against a genuinely strong quarter a year ago. In last year's first quarter, hemophilia grew roughly 8%. Since then, we've been carrying out the Kogenate Kovaltry switch here in the U.S., and obviously there is some loss as patients move over, but it's more or less consistent with our expectations. You should look for this business to keep going in much the same way through the rest of the year, quarter after quarter. Yes, it reflects tougher competition. Sanofi isn't the only one. Other products, from Roche for instance, are also continuing to hit our business hard here. None of it really comes as a surprise to us.

James Quigley

analyst
#39

Thanks a lot. Appreciate it.

Operator

operator
#40

Christian Faitz from Kepler Cheuvreux has the next question. Go ahead, please.

Christian Faitz

analyst
#41

Yes, thanks. Good afternoon, everyone. I have two questions, please. First, I'd like to return to what Michael asked about Crop Science volumes, especially chemicals. Could you assess how much of that volume drop stemmed from weather — that is, delays pushing into Q2, as happened in both of the Northern Hemisphere's key regions, with application significantly delayed? Then a second question for Werner, wearing his CFO hat: your interest expense came in considerably lower, both year on year and sequentially. How did you accomplish that amid rising interest rates, and also given your debt position — particularly on the shorter-term side — which has risen at least on a quarterly basis? That's all from me. All the best to Wolfgang, by the way. And obviously, Werner, all the best to you and your post-Bayer time.

Rodrigo Santos

executive
#42

Christian, let me return to the volume topic and add a bit more detail to the volume we touched on earlier. You made a good point about the weather, particularly if Argentina comes to mind as an example—a very drought-stricken season we had there. That had some effect on crop protection usage in that country. Argentina's drought is probably one we hadn't seen in the last 60 years. There was also some drought and some weather factors here in the U.S. that delayed part of the U.S. somewhat when it comes to the planting region. That affects volume, specifically the flow in the first quarter. I also mentioned a little about the fungicide. Fungicide is a particular one for us because of supply constraints, and we see that recovering at the end of the year as well. Also, if you think a little about our supply in glyphosate too, we're going to see some recovery as well when you compare quarters—Q4 versus last year as well.

Rodrigo Santos

executive
#43

That's the small piece of the flow you've got. Once more, I'm simply using your question to hammer that point home, correct? We observed an 8% expansion of the core business during the first quarter, and that's the reason we're confident about delivering 10% for the full year, since you've got pricing elements that are going to help. Let me offer one more pricing illustration — we've just launched the campaigns in Brazil. When I was last with you, it was about North America and Europe. We launched the prices in Brazil. Soybean, for instance, with our Intacta 2 Xtend expansion. We're at a mid-teens pricing increase. On the summer corn price in Brazil right now as well, we have a low double-digit price increase. Putting that together with the volumes I just mentioned gives us confidence for the full year in our 10% or double-digit growth on the core business. That's a little bit of a very important element that we talked about a lot with you on the last earnings as well. Thank you. Werner?

Christian Faitz

analyst
#44

Alright, thank you.

Werner Baumann

executive
#45

Okay, thanks — and Rodrigo, thank you as well. Christian, I appreciate your kind words too. What I'll do is address where we stand financially right now, and then offer a bit of a preview of what lies ahead, since I think that helps in this context. To start with, during the past year we deliberately raised extra liquidity at extremely low interest rates, essentially to build something of a cushion once the conflict in Ukraine began. The upshot is a net positive interest result for us: low cost on one side, and on the other, higher yields coming from that liquidity as it is currently invested. Second, we benefited from some favorable fair value movements in our financial assets, correct? That's what accounts for the positive financial result this quarter. Second, looking forward, what should rising interest rates mean for you? After accounting for the debt reduction we anticipate by the close of 2024, roughly EUR 7 billion needs refinancing, right? Measured across a full year, 200 additional basis points would translate to approximately EUR 140 million in extra cost, offset by EUR 100 million of interest savings from the EUR 3 billion we intend to retire, okay?

Werner Baumann

executive
#46

That is more or less neutral. Because we're only refinancing a portion of the maturities coming due later in 2023 and 2024, any first full-year effect wouldn't show up before 2025. The rest of our existing financial debt, you know, carries fixed rates. Right? No impact.

Christian Faitz

analyst
#47

All right, thanks a lot, Werner. That was really useful.

Werner Baumann

executive
#48

Thanks, Christian.

Operator

operator
#49

Kirsty Ross-Stewart from Citi has the next question. Please go ahead.

Kirsty Ross-Stewart

analyst
#50

Hello. Yes, this is Kirsty Ross speaking.

Operator

operator
#51

Mm-hmm.

Kirsty Ross-Stewart

analyst
#52

This is Peter Verdult from Citi, and I have just two questions, please. First, could you give us something of a preview before the Pharma R&D Day in June, and specifically, will you be in a position to share any new clinical data from the cell and gene therapy programs you have underway? Secondly, I know you mentioned strong patient recruitment in your prepared remarks regarding the OCEANIC program. I'm wondering if you can provide a little more detail here on how quickly the trials are enrolling versus your expectations. If this is, you know, so far, what level of enrollment have you achieved? Thanks very much.

Stefan Oelrich

executive
#53

Okay, hi Pete, and thanks for asking. I hope you’ll still show up in spite of these questions — and that all of you join us for our R&D day — so I probably shouldn’t say too much here. Regarding our cell therapy trial in Parkinson’s, the readout is unfortunately planned for the second half of the year. We’re assembling the data at the moment, and after that we need to present it, and the right venue for presenting it isn’t an R&D day — it’s the right context. That, unfortunately, I can’t provide you, but nothing bad should be read into that. As for the OCEANIC trial in atrial fibrillation, recruitment is ahead of schedule. I’m actually very pleased with how quickly this trial is recruiting. You know, we had expected a primary completion for the trial in the second half of 2025. We’re now racing to beat that. That obviously would be great news. It’s really going very nicely.

Kirsty Ross-Stewart

analyst
#54

I appreciate that.

Operator

operator
#55

Our next question comes from Sachin Jain at Bank of America. Please go ahead.

Joe Bowden

analyst
#56

Hello, this is Joe Bowden from Bank of America, sitting in for Sachin Jain. I have two questions about R&D, if that's alright. First, I was wondering whether you could share any detail on how R&D spending is phased across the year, since it was mentioned as a drag on OneQ earnings. Second, and building on that point, I was wondering if you have a view on where R&D spend and the bill might head, given the substantial growth we've witnessed at Roche during his tenure. Thank you.

Stefan Oelrich

executive
#57

Allow me to begin. During the first quarter, our R&D spending came to roughly 20%. The clear explanation for this is that you have the ability to increase or decrease it when your China sales rise unexpectedly within any given quarter. Since we anticipate catching up to our sales guidance, our R&D spend — which is around 17% for the full year — ought to normalize across the quarters as well. Now the second part of the question. Regarding where we're headed going forward, I believe it's somewhat early to tell, but I can say — and we've mentioned this before, I think, at the Capital Markets Day — that we clearly intend to transform into a far more specialty-oriented player, and that should open up room by strengthening our position in both cost of goods and marketing and sales expenses, which could then partly flow either toward margin or toward additional innovation investments within the R&D line. That is at least the long-term perspective.

Operator

operator
#58

Our next question comes from Jo Walton at Credit Suisse. Please go ahead.

Jo Walton

analyst
#59

Thank you. I’d like to ask a couple of questions on pharma and one on ag. Regarding Eylea, could you provide a bit more detail on where the growth is coming from and on the level of price decline you’ve experienced? Presumably, that price decline is tied to things such as generic Lucentis becoming available. Since you don’t yet have the new indications through, where are you getting the net new growth from? On the ag side, I wonder whether you could tell us a little more about whether there’s some sort of clearing event, or what we should watch for to give us a better sense of how you’re going to close out the longer-term litigation on glyphosate. We understand that you’re not paying out the short-term money as much as you might because you’re hoping that you might be able to get that reduced. A little more on when we could look for some clarity on that, please. Thank you.

Stefan Oelrich

executive
#60

Hi, Jo. Thanks for asking. It's a mixed picture, as always. Geographically speaking, we're seeing really nice numbers out of Asia, across the board, and that includes China, because we're starting from a low base with Eylea. Latin America and Canada are very good. Europe is a mixed picture, but mostly because of price decreases in the U.K. tied to VPAS. On a broader level, though, we're clearly still benefiting from our leadership position when it comes to new patients and new starts. And we believe we still hold the gold standard for data in this class, and that's reflected in our results. That covers Eylea. Okay, turning to ag, innovation, glyphosate replacement — Rodrigo.

Rodrigo Santos

executive
#61

I can say a few words on that. And Werner, if you'd like to add anything regarding the litigation she brought up, I'll hand it over to you as well. On the innovation side, we keep working on new herbicide models, correct? I believe that. We've just moved it forward, and this year we have trials with the new herbicide, which we still refer to as ICA 679. A commercial name hasn't been chosen yet. It's a new mode of action that the industry couldn't develop over the last 30 years. This new mode of action has us very excited. Launch should come at the end of the decade. I think it will be an interesting new herbicide on the market, broad spectrum. Again, as of today we don't foresee it replacing glyphosate. It will complement glyphosate, and I think that point matters. On the litigation, let me begin, and then Werner, you can comment on that too. Our five-point plan is being fully implemented. One very important piece of it is phasing glyphosate out of the lawn and garden market in the U.S., not because of safety, but simply to address the litigation.

Rodrigo Santos

executive
#62

That's a really key point. Naturally, we take a lot of pride in the fact that we also have the six wins on court, and we feel confident about our cases on that front. Werner, would you like to add anything on the litigation side as well?

Werner Baumann

executive
#63

Glad to do that, and let me add a bit. As Rodrigo said a moment ago, of the nine cases that have gone to trial, six have been wins for us so far. One is still underway — the Gordon trial — which begins in January, on June, on April 26th. That one is, you know, progressing as we anticipated. Another case, where jury selection was set to begin in Florida this week on May 8th, has now been vacated and pushed back indefinitely, which is welcome news. There are also other efforts underway consistent with the five-point plan we described to you. One of those is, naturally, working to bring one case or another before the Supreme Court. Carson is before the 11th Circuit, with oral argument set for June. We'd then anticipate a ruling in that matter around quarter four or quarter one 2024. That said, you know, those dates are, shall we say, rather hard to forecast, since the court faces no firm deadlines driving its schedule. Beyond Carson, we have several other paths to the Supreme Court. Aside from that, regarding the litigation still ongoing and the cases that remain outstanding, we are holding discussions with plaintiff lawyers, as you'd expect.

Werner Baumann

executive
#64

We won't accept, you know, unreasonable sums. Beyond that, as you're aware, we actually have a claims administration program of our own that's ready to launch whenever we determine that would be the appropriate step. Finally, the website we mentioned is now live. Rodrigo already addressed the new formulation. Aside from that, yeah, just to highlight it once more, regarding the safety assessment, no new development has emerged over the last years that would call into question glyphosate's safety and non-carcinogenicity. That gives us, let's say, a solid foundation to keep defending ourselves in this litigation and also to make, you know, some headway here.

Operator

operator
#65

Thanks. We'll take our next question from Andreas Heine at Stifel. Go right ahead.

Andreas Heine

analyst
#66

This actually covers both soybeans and corn. For corn, you've observed quite robust growth at +16%, while soybeans came in at just 1%. The soybean figure was a phasing effect. My question is whether that 16% in corn is also phasing, meaning it'll end up much lower, or whether it reflects the gain you likely have? Since you mentioned prices are probably around 10%, the 16% would then imply 6% volume growth. That's what I'm asking.

Rodrigo Santos

executive
#67

Thanks, Andreas. Let me pick up on your question, since I'd like to use it to give a bit of framing here. I see this as a great chance to reinforce part of the message. Over the past year — I've been in this role a touch more than one year now — we had plenty of discussion about how to grow the core business. Given how glyphosate grew, one of the main questions all of you raised was how we could drive core business growth this year, correct? I'm glad you asked it, because it reinforces this point somewhat. Corn. With corn, there are several elements. Pricing — I touched a bit on the pricing we have in North America and EMEA. I gave another figure today as well, on the low double-digit price increase we're implementing in the summer of Brazil, plus volume. We're seeing volume growth in the U.S. thanks to acreage recovering from last year. That's an important element for us to see. And then the launches we have, such as the Fox Xpro that Werner mentioned, with over 1 million acres under RNAi technology — that is helping us drive global share in corn.

Rodrigo Santos

executive
#68

We feel really good about that. You brought up volume in Q4 and Q1, and there's a piece of that which affects soybean too, correct? Soybean sales and deliveries were solid in Q4, and somewhat lower in Q1 in North America. Add to that the U.S. soybean acreage holding flat. Volumes are higher in Brazil, which reaffirms how soybean is performing in Latin America too. That's going to help a lot. And as I told you, we're seeing mid-teens price increases for Intacta 2 Xtend in Brazil, which is scaling up as we speak. Those corn and soybean points you raised simply help me confirm that the whole innovation engine we have, along with the new launches we're taking to market — and there's even more coming, right? I touched on this year too. Werner gave you the figure. We've got around 30,000 acres of farmer trials with short stature corn. We're excited, because this is the strongest demand technology we've seen over the last year. More is coming in the years ahead.

Rodrigo Santos

executive
#69

It's really encouraging to see how our core business has performed, confirming both our engine and our market leadership. Thank you so much.

Andreas Heine

analyst
#70

Perhaps to build on that point: what you're seeing with that 16% figure in corn really isn't connected to the same situation, nor does it reflect any genuine growth that we could anticipate for the Northern Hemisphere during the first half either.

Rodrigo Santos

executive
#71

Well, a lot of that comes down to pricing, right? As you said, let me check whether I've got your point here correctly. Pricing accounts for a big chunk of it. Our volume is higher in North America thanks to more corn acreage in the U.S., but volume is down in Ukraine because of the war. With the war in Ukraine, we'll probably see the corn area there reduced this year. Once you wash that out — higher volume in North America, lower volume in EMEA owing to the war in Ukraine — the main impact you saw on Q1 specifically comes mostly from pricing.

Andreas Heine

analyst
#72

Alright, thanks very much, Rodrigo.

Rodrigo Santos

executive
#73

Thanks, Andreas.

Operator

operator
#74

Our following question comes from Laurent Favre at BNP. Please proceed.

Laurent Favre

analyst
#75

Good afternoon. My first question goes to Rodrigo, and it concerns glyphosate, quite simply. Within the updated budget you've provided, which glyphosate EBITDA margin are you assuming, relative to the 25% divisional target? Is it considerably lower? Is it roughly aligned? That's my first one. Then, for Stefan regarding margins, could you help us grasp how distant from 29% you believe you'd stand in Q2? I don't believe I've heard you mention contingency cost-cutting. Are you working on something like that in case the sales recovery falls short? Thank you.

Rodrigo Santos

executive
#76

Let me begin with glyphosate, Laurent, okay? Essentially, from last year onward — and you're somewhat familiar with this — we gained from that price peak a year ago. This year, through this adjustment, we've taken it back to the early 21 levels, as I said earlier. Glyphosate, as you're aware, isn't a high-margin product; it's more of a commodity market. We understand how to run a business like that since we're extremely lean. Very few people handle glyphosate for us. We don't run many programs on it, and we maintain that approach. We always keep it that way. We won't alter it, given our high turnover. Margins are lower. It somewhat bolstered the core margin we hold. Considering the guidance we're presenting here, 25%, that's still far above any of our competitors, correct? In margin terms, we lead the industry, and I believe that's a really key point. Last year we finished far, far above the competitors. We anticipate the same this year. Cash flow is another area where we're seeing strong performance relative to the market.

Rodrigo Santos

executive
#77

My take is that under typical circumstances, glyphosate is a business with thin margins. We understand how to handle that — capturing the opportunities in strong years such as the one we had last year, and also running with a very lean, cost-effective organization to cope with the situation we're facing right now. Let me use your question to drive home one point. Naturally, 60% of glyphosate comes from China. Prices in the market aren't something we control. We're simply reporting what we see here. This represents our best estimate as of today. We'll keep monitoring and responding. We don't believe the Chinese will sell below cost. It matters to note that we do have that management of glyphosate, as I told you. Let me continue.

Stefan Oelrich

executive
#78

Thanks, Laurent. Like I mentioned, what we're seeing is improvement from one quarter to the next. Please don't count on us getting past 30% in Q2. When I describe it as sequential, that's exactly what I mean, and it ought to bring improvement, particularly during the back half once a few of those effects — the drag on the top line — fade away. That's the situation we're in.

Laurent Favre

analyst
#79

Thanks. On the cost reductions — what about the contingency planning?

Stefan Oelrich

executive
#80

Sorry, I didn’t hear that.

Laurent Favre

analyst
#81

Planning cost saving.

Stefan Oelrich

executive
#82

On the cost-saving side — honestly, whatever isn't customer facing, we already run that with a tight grip. So that's a standing habit, and I keep reminding my organization to stay at it, and we're always hunting for more. If that's what you mean by cost contingencies, then sure, but that's just how we normally operate. Yeah, Laurent, maybe I can add the whole-company angle to that as well. This year we're planning cost savings and efficiency programs of roughly EUR 700 million to EUR 800 million. That's up by around EUR 200 million versus the EUR 500 million to EUR 600 million we included in the full year guidance in February. Okay?

Rodrigo Santos

executive
#83

Yes. Exactly.

Laurent Favre

analyst
#84

Alright, thanks.

Oliver Maier

executive
#85

Thanks, Natalie. I believe we can fit in two additional questions.

Operator

operator
#86

Thanks. Our following question comes from Sebastian Bray at Berenberg. You have the floor.

Sebastian Bray

analyst
#87

Good afternoon, and thanks for taking my questions. I have two, please, both about agriculture. The first one is simply an update on the number of cases. Werner, I think the last time a figure was provided, you said roughly 150,000 glyphosate cases had been filed. Are we still in a situation where that figure holds, and of those, approximately 110,000 have been settled? That's my first question. The second one concerns soybean. I noticed that the statements about Bayer defending a leading market position in North American soybean were not repeated the way they were in 2022. Does Bayer still expect to be number one in this market by the end of 2023? Thank you.

Werner Baumann

executive
#88

I'll take the first question first, and then Rodrigo can handle your second one. Out of a total of 154,000, we've settled roughly 109,000. As for how quickly settlements happen, that depends on plaintiff lawyers being reasonable with what they ask for. We're not rushing to pay premium dollars for, say, mediocre inventories of cases. That's the situation. Progress will only happen to the degree that we consider it reasonable, economically sensible, and meaningful. If not, we won't be settling cases.

Rodrigo Santos

executive
#89

Moving on to soybeans—

Werner Baumann

executive
#90

Rodrigo.

Rodrigo Santos

executive
#91

Okay, on soybeans, Sebastian — thanks for that question. If you look at how we closed out last year, as you pointed out, we had a soybean business worth EUR 2.5 billion, which is the biggest soybean business out there. Our second-place competitor sits below EUR 2 billion. Globally, we remain the leader in soybean for sure, with a clear edge in Latam, which is an important market for us — especially with the launch of Intacta 2 Xtend broadening the penetration we have with Intacta. We're getting ready right now to launch Intacta 3 and Intacta 4, for the third and fourth generations coming down the line. In the U.S., our market is more balanced, with the competitor platform expanding. We're still the number one platform for farmers. We see a lot of that term. Clearly, what's happened over the past few years is that Corteva was using Xtend, and now they're using Enlist, so they're moving their own portfolio from one platform over to another. We see a more balanced market in the U.S., and we're still leading that market, and we expect to keep seeing that in the years ahead as well with the new launches. I mentioned the launches in Latin America. Let me reinforce that in the years to come, we're going to launch ATT 4 in the U.S.

Rodrigo Santos

executive
#92

That gives farmers a genuinely strong platform, since there are five modes of action for weed control, and we think that will prove a highly interesting technology for growers, offering plenty of flexibility. Thanks also for your question, Sebastian.

Sebastian Bray

analyst
#93

Appreciate that — thanks, and best of luck to you too, Werner.

Operator

operator
#94

The final question comes from Vincent Andrews at Morgan Stanley. Your line is open.

Vincent Andrews

analyst
#95

Thanks for taking my question. Rodrigo, I was wondering whether you could give some context on the generic glyphosate price that currently exists out there, the one you're pricing above. How much margin do you figure that still leaves for the Chinese producer or the generic producer? I'm just trying to get at how confident you are that the pricing assumptions you've baked into the back half of the year don't carry any negative wiggle room if competition heats up or volume is weak for weather reasons or whatever else.

Rodrigo Santos

executive
#96

Vincent, that is a tough one to answer. We do carry out some cost evaluation for China. We keep an eye on a bit of that — the public data on pricing, exports, and so forth. It is difficult. Our view is that today's prices leave a very thin margin for gene-generics, which is why I said we do not expect they will drop below that. Well, again, this is not something we control, and we do not anticipate they will fall under cost over the coming months or thereabouts. Again, a very hard question for me to answer for you. What I sense is that we are at the levels seen, as you know, at the earliest in 2021. I think that given current inflation and cost, this is what we regard as a low margin for generics in China. That is why we made the adjustment to the guidance here. We will keep watching that, Vincent. It is very difficult to predict what China will do. We are monitoring very closely. We are adjusting our premium prices relative to the generics, as you know. We are competing in the right market. We stay with the same strategy on lean, fast, agile, and glyphosate, reacting wherever we need to. Hopefully, this will help us steer the year toward the end of the year and also a little on the volume plans we have for Latam.

Rodrigo Santos

executive
#97

That's a really tough one to respond to, Vincent, but we think there's a bit of it I'm able to share with you today.

Vincent Andrews

analyst
#98

Alright, thank you so much. I appreciate you taking the question, and I’m looking forward to catching everyone next month.

Rodrigo Santos

executive
#99

Thanks so much, Vincent. I hope all of you can join us on June 20 in New York. It'll be really nice to give you a bit of our perspective on the 10-year plans we have for our innovation and our pipeline. We're excited to share more information with you at that event.

Operator

operator
#100

Since time is short, we need to wrap up the Q&A session, and I'll turn things back over to Oliver Maier for closing remarks.

Oliver Maier

executive
#101

Thanks. Appreciate it, Natalie, and thanks to everyone for spending time with us today—we really value it. That said, I've got a very special closing note today, since as you all probably are aware, Werner, this marks your final quarterly conference call. On behalf of all the Bayer colleagues here, I'd also like to express our thanks for your experience, your support, and your leadership across the years we've worked together. Many thanks, and we wish you the very best in whatever you take on next. Thank you so much.

Rodrigo Santos

executive
#102

Thanks. Wishing everyone on the call the very best.

Operator

operator
#103

That brings us to the end of Bayer AG's investor and analyst call for the first quarter of 2023, ladies and gentlemen. We appreciate your participation. You're welcome to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.